Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Amyloid Threshold Hypotheses for Donanemab\n\n## Executive Summary\n\nThe research gap you've identified is among the most operationally critical outstanding questions in anti-amyloid therapeutics. Current FDA approval language permits stopping when amyloid is \"clinically appropriate,\" but this ambiguity creates real-world prescribing chaos. The hypotheses presented are mechanistically intriguing but carry significant translational gaps. I'll prioritize based on *what can actually move clinical practice within the next 5 years.*\n\n---\n\n## Part 1: Hypotheses with Highest Translational Potential\n\n### Hypothesis A: CSF p-tau217 as Surrogate Threshold Marker\n\n**Why This Has Highest Translational Potential:**\n\nWhile the Theorist focused on synaptic markers, the current biomarker landscape strongly favors phosphorylated tau as the primary therapeutic monitoring tool. The mechanism is straightforward: amyloid reduction precedes tau reduction in the causal cascade, making p-tau217 a downstream integrator of both amyloid clearance and downstream neurodegeneration.\n\n**Current Clinical Evidence:**\n- P-tau217 demonstrates 85-90% sensitivity/specificity for amyloid positivity (Jansen et al., 2022; Palmqvist et al., 2020)\n- In TRAILBLAZER-ALZ 2, plasma p-tau217 declined significantly with donanemab treatment and correlated with amyloid change\n- The phase 2 data suggest p-tau217 normalization may precede or parallel cognitive stabilization—making it a candidate for threshold-based stopping rules\n- Multiple CLIA-certified plasma assays now available (ALZpath, Fujirebio, Roche)\n\n**Safety Considerations:**\n- Low-risk biomarker monitoring—blood draw poses no direct patient harm\n- Potential indirect risk: if stopping rules are too aggressive, patients might discontinue treatment before full benefit achieved\n- Conversely, stopping at wrong threshold could leave patients with ongoing amyloid-mediated toxicity\n\n**Patient Population Fit:**\n- Excellent fit for early symptomatic AD (MCI-mild dementia) as studied in TRAILBLAZER-ALZ 2\n- Challenging for preclinical populations where p-tau217 may not yet be elevated\n- Particularly relevant for APOE4 carriers, who show different tau trajectories\n\n**Translational Pathway:** The most actionable hypothesis because:\n1. Assays are already validated and commercially available\n2. Correlation with clinical endpoints exists in Phase 2/3 data\n3. Could be incorporated into treatment guidelines within 2-3 years with prospective validation\n\n---\n\n### Hypothesis B: Minimal Chronic Amyloid Burden (MCAB) Model\n\n**Why This Des",
  "tokens_used": "649"
}